Table 3.
Mean blood glucose concentration and daily insulin doses during subcutaneous insulin treatment after resolution of DKA
| Mean daily blood glucose (mg/dl) |
P | Mean daily insulin dose (units/day) |
P | |||
|---|---|---|---|---|---|---|
| NPH/regular | Glargine/glulisine | NPH/regular | Glargine/glulisine | |||
| Day 1* | 188 ± 61 | 213 ± 76 | 0.234 | 50 ± 28 | 58 ± 33 | 0.304 |
| Day 2 | 206 ± 71 | 220 ± 61 | 0.370 | 70 ± 37 | 73 ± 47 | 0.877 |
| Day 3 | 207 ± 86 | 180 ± 80 | 0.417 | 77 ± 45 | 62 ± 49 | 0.364 |
| Day 4 | 211 ± 63 | 158 ± 44 | 0.068 | 70 ± 47 | 67 ± 50 | 0.999 |
| Day 5 | 190 ± 45 | 124 ± 41 | 0.068 | 50 ± 30 | 47 ± 41 | 0.302 |
Data are means ± SD.
*Day 1 = depending on the time of resolution of ketoacidosis and transition to subcutaneous insulin, a patient could have received one or two doses of NPH/regular insulin or one dose of glargine and one to three doses of glulisine insulin per day.